NIFTY 50 22795.9 ▼ (0.51%)
NIFTY NEXT 50 60466.8 ▼ (0.94%)
NIFTY 100 23274.05 ▼ (0.59%)
NIFTY MIDCAP 100 50486.2 ▼ (1.32%)
NIFTY SMALLCAP 100 15636.9 ▼ (0.7%)
NIFTY SMALLCAP 250 14683.4 ▼ (0.57%)
NIFTY MIDCAP SELECT 11198.9 ▼ (1.69%)
NIFTY TOTAL MARKET 11634.25 ▼ (0.67%)
NIFTY BANK 48981.2 ▼ (0.72%)
SENSEX 75311.06 ▼ (0.56%)
BSE BANKEX 55718.18 ▼ (0.82%)

Ishita Drugs & Industries : Q4 2024 Financial Quarterly Report : YoY Sales Up 71.15 %, QoQ Up 40.06 %

July 3, 2024July 3, 2024| adminadmin| 0 Comments| 2:05 pm
Image is loading
Categories:

Share the post "Ishita Drugs & Industries : Q4 2024 Financial Quarterly Report : YoY Sales Up 71.15 %, QoQ Up 40.06 %"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter: The company experienced a substantial growth of 71.15 % in the past year, substantial increase in net sales/revenue by 40.06 %.
  • Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 11.11 %. Marginal increase in other income during this quarter, up by 900%.
  • Profit over the Year and quarter: Significant improvement in profitability for Ishita Drugs & Industries Ltd.. Notable increase of 57.54 % in net profit Year to Year, Ishita Drugs & Industries Ltd.’s profitability increased by 136.97 % in this quarter.
  • EPS over the Year and quarter: EPS increased by 56.67 % Year to Year. EPS increased by 135 % in previous quarter. Positive impact on shareholders.

The comprehensive analytics outlining the performance and outlook of Ishita Drugs & Industries Ltd.”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 2.627 Cr Rs. 3.21 Cr Rs. 4.496 Cr + 40.06 % + 71.15 %
Expenses Rs. 2.39 Cr Rs. 2.98 Cr Rs. 4.2 Cr + 40.94 % + 75.73 %
Operating Profit Rs. 0.24 Cr Rs. 0.23 Cr Rs. 0.3 Cr + 30.43 % + 25 %
OPM % 9.14 % 7.17 % 6.67 % -0.5 % -2.47 %
Other Income Rs. 0.09 Cr Rs. 0.01 Cr Rs. 0.1 Cr + 900 % + 11.11 %
Interest Rs. 0.04 Cr Rs. 0.04 Cr Rs. 0.02 Cr -50 % -50 %
Depreciation Rs. 0.03 Cr Rs. 0.03 Cr Rs. 0.01 Cr -66.67 % -66.67 %
Profit before tax Rs. 0.26 Cr Rs. 0.17 Cr Rs. 0.37 Cr + 117.65 % + 42.31 %
Tax % 28.69 % 25.63 % 23.78 % -1.85 % -4.91 %
Net Profit Rs. 0.18 Cr Rs. 0.12 Cr Rs. 0.28 Cr + 133.33 % + 55.56 %
EPS in Rs Rs. 0.6 Rs. 0.4 Rs. 0.94 + 135 % + 56.67 %


Today, we’re looking at Ishita Drugs & Industries Ltd.’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 71.15 %. However, it did see a marginal increase of 40.06 % from the previous quarter. Expenses ticked up slightly by 40.94 % quarter-on-quarter, aligning with the annual rise of 75.73 %. Operating profit, while up 25 % compared to last year, faced a quarter-on-quarter increase of 30.43 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -2.47 %, but a shrinkage of -0.5 % sequentially. Other income rose by 900 % compared to the last quarter, despite an annual growth of 11.11 %. Interest expenses dropped significantly by -50 % from the previous quarter, yet the year-over-year decrease remains at a moderate -50 %. Depreciation costs fell by -66.67 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -66.67 %. Profit before tax grew annually by 42.31 % but saw an increase from the preceding quarter by 117.65 %.
Tax expenses as a percentage of profits decreased slightly by -4.91 % compared to last year, with a more notable quarter-on-quarter decrease of -1.85 %. Net profit rose by 55.56 % year-on-year but experienced a 133.33 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 56.67 % but a quarterly rise of 135 %. In summary, Ishita Drugs & Industries Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 2.627 Cr Rs. 3.21 Cr Rs. 4.496 Cr + 40.06 % + 71.15 %
Expenses Rs. 2.39 Cr Rs. 2.98 Cr Rs. 4.2 Cr + 40.94 % + 75.73 %
Operating Profit Rs. 0.24 Cr Rs. 0.23 Cr Rs. 0.3 Cr + 30.43 % + 25 %
Net Profit Rs. 0.18 Cr Rs. 0.12 Cr Rs. 0.28 Cr + 133.33 % + 55.56 %
EPS in Rs Rs. 0.6 Rs. 0.4 Rs. 0.94 + 135 % + 56.67 %


In reviewing Ishita Drugs & Industries Ltd.’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 71.15 % year-on-year growth, however, there was a minor increase of 40.06 % from the previous quarter. Expenses rose by 75.73 % compared to the previous year, with a 40.94 % increase quarter-on-quarter. Operating Profit surged by 25 % annually, and saw a 30.43 % increase from the last quarter.
Net Profit showed yearly increase of 55.56 %, and experienced a 133.33 % increase from the previous quarter. Earnings Per Share (EPS) rose by 56.67 % annually, however rose by 135 % compared to the last quarter. In essence, while Ishita Drugs & Industries Ltd. exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”Ishita Drugs & Industries “]

Related Post